In a previous study, EGFR was hyperphosphorylated in 4 out of 5 tumours from patients with acquired or intrinsic resistance to vemurafenib, leading to a hyperactivation of the STAT3 pathway [15]. This evidence concerns the gene STAT3 and neoplasm.